Penicillin acylase mutant and application thereof

By mutation of penicillin acylase, catalyzing the reaction of β-lactam raw material and acyl donor in one step, solving the problems of complex production processes and intermediate separation in the prior art, and improving β-lactams Antibiotic synthesis efficiency and cost-effectiveness.

CN119020335AActive Publication Date: 2024-11-26ZHEJIANG NORMAL UNIV XINGZHI COLLEGE

Patent Information

Application Number
CN202411396069.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-08
Publication Date
2024-11-26
Estimated Expiration
2044-10-08

AI Technical Summary

Technical Problem

In the prior art, the production process of β-lactam antibiotics is complex, requiring two-step reactions and intermediate separation, resulting in low efficiency and high cost.

Method used

By mutation of the penicillin acylase, a mutant can catalyze the reaction of β-lactam raw material and acyl donor in one step, achieving rapid and efficient synthesis of semi-synthetic β-lactam antibiotics.

Benefits of technology

The production process is simplified, the reaction product yield is improved, the production cost is significantly saved, and the innovation of β-lactam antibiotic preparation technology is promoted.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020335A_ABST
    Figure CN119020335A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of enzyme catalysis, and particularly relates to a penicillin acylase mutant and application thereof. Compared with an amino acid sequence as shown in SEQ ID NO.1, the mutant comprises at least one of the following mutation sites: F146 [alpha] K, F24 [beta] R, F71 [beta] Y, N241 [beta] K, G385 [beta] Y or G385 [beta] R. According to the penicillin acylase mutant disclosed by the invention, penicillin acylase from kluyvera citrophila (Kluyvera citrophila) is mutated, so that the penicillin acylase mutant which is strong in hydrolytic activity and synthetic activity and is coordinated in two enzyme activities is obtained. The method can be used for synthesis production of beta-lactam antibiotics, especially for one-step preparation of amoxicillin by catalyzing penicillin potassium salt and the like, and separation of an intermediate 6-APA is avoided. The invention provides a key enzyme for efficient preparation of beta-lactam antibiotics, and greatly promotes the innovation of a beta-lactam antibiotic preparation technology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of enzyme catalysis, and in particular relates to a penicillin acylase (PA) mutant and application thereof. Background Art

[0002] β-lactam antibiotics (β-lactams) refer to a large class of antibiotics with a β-lactam ring in their chemical structure. This class of antibiotics has the advantages of strong bactericidal activity, low toxicity, wide indications and good clinical efficacy. However, naturally occurring β-lactam antibiotics (such as penicillin and cephalosporin) have the disadvantages of narrow antibacterial spectrum, acid resistance, easy to develop drug resistance and easy to cause allergic reactions. Semi-synthetic β-lactam antibiotics such as semi-synthetic penicillin and semi-synthetic cephalosporin have overcome these shortcomings and have become the main antibiotics used in the current medical field.

[0003] The use of enzyme catalysis technology to prepare semi-synthetic β-lactam antibiotics can produce semi-synthetic β-lactam antibiotics more efficiently, greenly and sustainably, and the quality of the prepared products is better than that of traditional chemical synthesis methods. Penicillin acylase is a key enzyme that catalyzes the synthesis of such products. The enzyme-catalyzed synthesis of semi-synthetic penicillins such as ampicillin and amoxicillin currently consists of a two-step process, namely, firstly, penicillin acylase is used to hydrolyze penicillin and its salts (to prepare 6-APA (6-aminopenicillanic acid), and then penicillin acylase is used to synthesize 6-APA to react with an acyl donor side chain (such as D-p-hydroxyphenylglycine methyl ester) to prepare semi-synthetic β-lactam antibiotics. Semi-synthetic cephalosporins are mainly produced by penicillin acylase catalyzing the reaction of cephalosporin intermediate nuclei such as 7-ACA and 7-ADCA with acyl donors. Penicillin acylase (Penicillin Acylase, PA, EC3.5.1.11) is the key enzyme of the preparation technology. The current existing technology uses two enzymes, penicillin acylase for hydrolysis and penicillin acylase for synthesis, to catalyze the hydrolysis preparation of 6-APA (or 7-ACA, 7-ADCA) and the synthesis of the intermediate nucleus and side chain in two steps. The two-step reaction not only has a long reaction process, but also requires the separation of the intermediate, and the production process is relatively complicated. Summary of the invention

[0004] In view of the problems existing in the prior art, the present invention provides a penicillin acylase mutant and its application, aiming to solve the problems in the prior art. The mutant provided by the present invention can catalyze the reaction of β-lactam raw materials including penicillin or cephalosporin and activated acyl donors to synthesize semi-synthetic β-lactam antibiotics, including semi-synthetic penicillin and semi-synthetic cephalosporin, and realize a new technology for the rapid and efficient synthesis of semi-synthetic β-lactam antibiotics.

[0005] The present invention is achieved by a penicillin acylase mutant, which comprises at least one of the following mutation sites compared with the amino acid sequence shown in SEQ ID NO.1: F146αK, F24βR, F71βY, N241βK, G385βY, G385βR. Amino acid abbreviations: F: phenylalanine; K: lysine; R: arginine; Y: tyrosine; N: asparagine; G: glycine.

[0006] The present invention also protects a nucleotide encoding any one of the above-mentioned penicillin acylase mutants.

[0007] The present invention also provides the use of the above penicillin acylase mutant in the preparation of β-lactam antibiotics.

[0008] Further, the β-lactam antibiotics include semi-synthetic penicillins and semi-synthetic cephalosporins. Semi-synthetic penicillins include amoxicillin, ampicillin or pimicilan; semi-synthetic cephalosporins include cephalexin, cefprozil, cefaclor, cephradine, cefadroxil, cefamandole, cefazolin, cefonic acid, cephalothin or cephalosporin.

[0009] Furthermore, only any one of the penicillin acylase mutants is used as the only penicillin acylase in the reaction system to catalyze the reaction between penicillin potassium salt and acyl donor to synthesize semi-synthetic penicillin β-lactam antibiotics in one step.

[0010] Further, the acyl donor includes phenylglycine methyl ester or p-hydroxyphenylglycine methyl ester.

[0011] Furthermore, any one of the penicillin acylase mutants is used as penicillin acylase to catalyze the reaction of 7-ACCA or 7-ADCA with phenylglycine methyl ester to synthesize semi-synthetic cephalosporin β-lactam antibiotics.

[0012] The invention mutates the amino acids in the substrate binding region of the wild-type penicillin acylase to improve the binding performance with the substrate and reduce the substrate binding steric hindrance effect; at the same time, the substrate-active site transition state free energy of the active center is reduced to promote the conversion of the intermediate state to the product, thereby promoting the accumulation of the final product, and finally greatly improving the ability of penicillin acylase to synthesize semi-synthetic β-lactam antibiotics.

[0013] In summary, the advantages and positive effects of the present invention are as follows: the present invention obtains a penicillin acylase mutant with strong hydrolysis activity and synthesis activity, coordinated two activities and better stability by mutating the penicillin acylase derived from Kluyvera citrophila. It can be used for the synthesis of β-lactam antibiotics such as semi-synthetic penicillins (such as amoxicillin, ampicillin or pimicilan), semi-synthetic cephalosporins (such as cephalexin, cefprozil, cefaclor, cephradine), and the one-step preparation (synthesis) of amoxicillin and ampicillin by penicillin potassium salt, etc., avoiding the separation of intermediates such as 6-APA. The present invention provides a key enzyme for the efficient preparation of β-lactam antibiotics, which will greatly promote the technological innovation of the preparation of β-lactam antibiotics. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 is the wild-type penicillin acylase amino acid sequence;

[0015] Figure 2 is a schematic diagram of the construction of the recombinant plasmid pET28a-kcPA;

[0016] Figure 3 This is the agarose electrophoresis detection diagram of the recombinant plasmid PCR;

[0017] Figure 4 This is the SDS-PAGE electrophoresis of protein expressed by E.coli BL21(DE3) / pET28a-kcPA bacteria;

[0018] Figure 5 This is the HPLC chromatogram of the one-step synthesis of amoxicillin by KcPA-catalyzed penicillin potassium salt in Example 3;

[0019] Figure 6 The content of each substance changes during the reaction of Example 4;

[0020] Figure 7 The content of each substance changes during the reaction of Example 5;

[0021] Figure 8 The content of each substance changes during the reaction of Example 6;

[0022] Fig. 9 It is the change of the content of each substance during the reaction process of Example 7. DETAILED DESCRIPTION

[0023] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers used in this application to express the amount, percentage, and other numerical values ​​should be understood as modified by the word "approximately" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties attempted to be obtained. Each numerical parameter should at least be regarded as obtained based on the reported significant figures and by conventional rounding methods. In the present invention, "about" means within 10% of a given value or range, preferably within 5%.

[0024] When the temperature is not particularly limited in the following embodiments of the present invention, it is all room temperature conditions. Room temperature refers to the natural room temperature conditions in the four seasons, without additional cooling or heating treatment, and is generally controlled at 10-30°C, preferably 15-25°C. The abbreviations have the following meanings: "min" means minute, "s" means second, "U" means enzyme activity unit, "mM" means millimole per liter, "M" means mole per liter, "rpm" means revolutions per minute, "mol" means mole, "μg" means microgram, "mg" means milligram, "g" means gram, "μL" means microliter, "mL" means milliliter, "bp" means base pair, LB medium means Luria-Bertani medium, and Kan50 means that the medium contains 50μg / mL karanomycin.

[0025] In the examples, the experimental methods without specifying the specific conditions are usually carried out according to conventional conditions, such as the methods described in the Molecular Cloning Laboratory Manual (Chinese version) (J. Sambrook, MR Green, ed., translated by He Fu. Fourth edition, Beijing: Science Press, 2017) and New England Biolabs (NEB) kits.

[0026] The present invention discloses a penicillin acylase mutant and its application. The technical solution provided by the present invention can avoid the separation of intermediates, greatly simplify the production process, and at the same time improve the yield of the reaction product, significantly save the production cost, and bring about a revolutionary change in the semi-synthetic antibiotic industry. The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention.

[0027] Example 1

[0028] Construction, prokaryotic expression and functional characterization of a mutant of penicillin acylase from Kluyvera citrophila

[0029] 1. Construction of wild-type PA expression vector pET28a-kcPA

[0030] The wild-type penicillin acylase used in this example is derived from Kluyvera citrophila K. citrophila ATCC21285, and its amino acid sequence is shown in SEQ ID NO. 1. The amino acid sequence consists of four parts, which are: a signal peptide at positions 1 to 26, an α subunit consisting of 209 amino acids at positions 27 to 235, an intermediate connecting peptide consisting of 54 amino acids at positions 236 to 289, and a β subunit consisting of 557 amino acids at positions 290 to 846 (see also Figure 1 , where the single underlined part is the α subunit, the wavy part is the connecting peptide, and the double underlined part is the β subunit), the nucleotide sequence is shown in SEQ ID NO.2.

[0031] The schematic diagram of the construction of the recombinant plasmid pET28a-kcPA is as follows Figure 2 Using the genome of K. citrophila ATCC21285 as a template, primers were designed based on the PA nucleotide sequence (SEQ ID NO.2), and the forward primer was: 5'-CG G / AATTC ATGAAAAACCGCAATCGCAT-3', SEQ ID NO.3; reverse primer is 5'-CC A / AGCTT TTAGCGCTGCACCTGCAGC-3', SEQ ID NO. 4. EcoR I and HindIII restriction enzyme sites were introduced respectively (the underlined bases are restriction endonuclease recognition sites), and the wild-type PA target fragment was amplified by PCR.

[0032] PCR reaction system:

[0033]

[0034] The PCR temperature program was designed as follows:

[0035]

[0036] Select EcoRI and HindIII restriction endonucleases to double-digest the blank plasmid pET28a vector and the target fragment. Double-digestion system:

[0037]

[0038] The double enzyme digestion was reacted at 37°C for 1 hour and then inactivated at 80°C for 20 minutes. The double enzyme digestion products were purified and recovered, and the concentrations were estimated based on the gel electrophoresis diagram, and the concentration of the plasmid pET28a was about 50 ng / μL, and the concentration of the target gene kcPA was about 140 ng / μL.

[0039] The double-digested products were ligated overnight using T4 DNA ligase in a 16°C metal bath to obtain the recombinant plasmid pET28a-kcPA, which was then heat-transformed into competent cells E. coli DH5α.

[0040] Target fragment and linearized vector connection system:

[0041]

[0042] To verify whether the recombinant plasmid was successfully transferred, a single colony was picked from the LB plate containing Kan50 and transferred to the LB liquid medium containing Kan50. The next day, the plasmid was extracted using a plasmid extraction kit, and PCR was performed on it. The target band of 2500 bp was obtained by agarose electrophoresis (such as Figure 3 ). The verified expression vector pET28a-kcPA was transformed into E. coli BL21 (DE3) to obtain the wild-type PA expression recombinant bacteria E. coli BL21 (DE3) / pET28a-kcPA.

[0043] 2. Obtaining mutant expression vector

[0044] In this example, 18 mutants were obtained by site-directed mutagenesis, as shown in the following table, where "F146αK" indicates that the 146th amino acid on the α subunit mutated from F to K, and the interpretation of other mutation sites is similar.

[0045] Table 1 Mutants and corresponding mutation sites

[0046]

[0047]

[0048] First, primers corresponding to each mutation site were designed, and then the wild-type PA target fragment was used as the initial template. Site-Directed Mutagenesis Kit (Q5 SDM Kit) was used for site-directed mutagenesis. The primers for each mutation site are as follows (lowercase letters represent the bases at the mutation site):

[0049] F146αK, F: 5'-GGCGAACCGTaaaTCTGACAGCACCAG-3', SEQ ID NO.5;

[0050] R: 5'-ATGGTGCCGACAAAAATCATCGCCA-3', SEQ ID NO.6;

[0051] F24βR, F: 5'-TGGGCCGCAGcgcGGTTGGTATGCG-3', SEQ ID NO.7,

[0052] R: 5'-TTGACCATAATGGCCTTCGCATCCT-3', SEQ ID NO.8;

[0053] F71βY, F: 5'-CACCGCCGGTtatGGTGATGATG-3', SEQ ID NO.9,

[0054] R: 5'-GATCCCCCATGAAATGGTGCCGTTGT-3', SEQ ID NO.10;

[0055] N241βK, F: 5'-CGCCAACTGGaaaAACTCGCCGC-3', SEQ ID NO.11,

[0056] R: 5'-ATATAGCCCGACTGCGGGTTATACAC-3', SEQ ID NO. 12;

[0057] G385βY: F: 5'-CGGGCCAACCtatTCGCTGAACATCAGCGTG-3', SEQ ID NO.13,

[0058] R: 5'-TCCTGGGTGGTTTCATAGCCACTGG-3', SEQ ID NO.14;

[0059] G385βR, F: 5'-CGGGCCAACCcgcTCGCTGAACATC-3', SEQ ID NO.15,

[0060] R: 5'-TCCTGGGTGGTTTCATAGCCACTGG-3', SEQ ID NO.16;

[0061] The primers were synthesized by a nucleic acid synthesis company, then dissolved in sterile water, and then operated according to the kit. As follows:

[0062] ①Use PCR to mutate the corresponding sites

[0063] PCR reaction system:

[0064]

[0065] Cycle program temperature:

[0066]

[0067]

[0068] For mutants with more than two mutation sites, the PCR product of the previous mutation site was used as a template to perform site-directed mutagenesis of the corresponding sites one by one.

[0069] ② Kinase, Ligase & DpnI (KLD) (a special mixture of kinase, ligase and DpnI) reaction treatment

[0070] The reaction system is as follows:

[0071] volume Final concentration PCR products 1μL 2X KLD Reaction Buffer 5μL 1X 10X KLD Enzyme Mix 1μL 1X Nuclease-free water 3μL

[0072] React at room temperature for 5 min.

[0073] ③ Heat shock transformation

[0074] Add 5 μL of KLD reaction mixture to 50 μL of chemical competent cell E. coli BL21 (DE3) suspension, incubate on ice for 30 min, heat shock at 42°C for 30 s, incubate on ice for 5 min, add 950 μL of SOC sterile liquid medium, and gently shake at 37°C for 1 h. Spread 40-100 μL of bacterial suspension on Kan50 LB plate, incubate at 37°C overnight, and the single colonies grown are the corresponding mutant expression strains, named E. coli BL21 (DE3) / pET28a-kcPA01~18

[0075] ④ Mutant identification

[0076] The mutant expression strain was inoculated into 25 mL of LB liquid medium containing Kan50, cultured overnight at 37°C, and the plasmid was extracted using a plasmid extraction kit. The plasmid was sent to a third-party biological company for sequencing to confirm that the corresponding product was the target product of the site-directed mutation.

[0077] 3. Expression of wild-type and mutant KcPA

[0078] The constructed recombinant E. coli BL21 (DE3) / pET28a-kcPA and E. coli BL21 (DE3) / pET28a-kcPA01 ~ 18 were inoculated on LB agar plates with Kan50 and cultured in a 37 ° C incubator for 12-16 hours. Pick a single colony and inoculate it into 25 mL of LB liquid culture medium with Kan50, and culture it overnight at 37 ° C and 300 rpm on a shaker. Pipette 500 μL of bacterial solution and transfer it to 50 mL of LB liquid culture medium with Kan50, culture it at 37 ° C and 280 rpm on a shaker, and monitor the OD 600, when it reaches 0.6-0.8, add IPTG solution to make the IPTG induction concentration 0.3mM, induce expression in a shaker at 25℃ and 220rpm for 10h, and collect the bacteria by centrifugation. The collected bacterial cells were suspended in pH7.5 PBS buffer and pre-cooled on ice for 10min, and then centrifuged at 4℃ and 12000rpmin for 6min to collect the bacteria. Add 50mM pH 7.5 PBS buffer to resuspend the bacteria in the centrifuge tube, and then centrifuge at 4℃ and 12000rpm for 6min, discard the supernatant, collect the final bacteria and resuspend them at a concentration of 0.01g / mL, and use an ultrasonic disruptor to disrupt the cells. The cell disruption conditions are: ice water bath, at 400W power, each cycle works for 3s, rests for 5s, and a total of 80 cycles. The mixture after crushing was centrifuged at 4°C and 12000 rpm for 15 min to obtain the supernatant, which was the crude enzyme solution. The crude enzyme solution was collected and the expressed protein was analyzed by SDS-PAGE.

[0079] Figure 4 It is the SDS-PAGE diagram of the protein expressed by the bacteria; wherein, lane M is the protein marker; Lane 1: E.coliBL21(DE3) / pET28a expression supernatant; Lane 2: E.coli BL21(DE3) / pET28a-kcPA uninduced supernatant; Lane 3: uninduced E.coli BL21(DE3) / pET28a-kcPA18 supernatant; Lane 4: IPTG-induced E.coli BL21(DE3) / pET28a-kcPA18 supernatant.

[0080] Example 2

[0081] 1. Determination of KcPA hydrolysis activity

[0082] The principle of the assay is: penicillin (PGK) potassium salt is hydrolyzed under the action of KcPA to generate 6-aminopenicillanic acid (6-APA) and phenylacetic acid. 6-APA reacts with p-dimethylaminobenzaldehyde (PDAB) under acidic conditions to generate a yellow-green substance with a maximum absorption peak at 415nm. Enzyme activity definition: At 28°C and 0.1M PBS buffer, the amount of enzyme required for penicillin acylase to catalyze 20mg / mL PGK to generate 1μmol 6-APA per minute is 1 unit of KcPA enzyme activity, the unit is U.

[0083] Weigh 0.5g PGK and dissolve it in the above buffer solution, and adjust the volume to 25mL. Pipette 2mL PGK solution into a centrifuge tube and add 0.1mL KcPA enzyme solution. Set up a control group without adding KcPA, and keep other conditions the same.

[0084] The reaction system was placed in a water bath shaker at 28°C and 200 rpm for 10 minutes. After the reaction, the enzyme was inactivated in a water bath at 90°C for 2 minutes. 200 μL of the reaction solution was added to 3 mL of pH 3.0, 0.1 M sodium citrate buffer, and 1 mL of a colorimetric solution (0.5% PDAB). After standing at room temperature for 3 minutes, the absorbance was measured at 415 nm. The 6-APA concentration in the sample after the reaction was obtained according to the 6-APA standard curve, and the enzyme activity, i.e., the hydrolysis activity, was calculated according to the formula.

[0085] Calculation formula: Penicillin acylase hydrolase activity per mL

[0086] In the formula, C 6-APA : 6-APA concentration in the sample, μmol / L; V: reaction system volume, mL; V E : amount of penicillin acylase added, mL; t: reaction time, 10 min.

[0087] 2. Determination of KcPA synthesis activity

[0088] 6-aminopenicillanic acid (6-APA) and 4-hydroxyphenylglycine methyl ester (DHPGM) synthesize amoxicillin under the action of KcPA. The amoxicillin content can be determined by high performance liquid chromatography to calculate the PA synthesis activity. Enzyme activity is defined as: under certain conditions, the unit of penicillin acylase catalyzes the production of 1 μmol of amoxicillin per minute, which is 1 unit of synthetic enzyme activity, represented by U.

[0089] Weigh 1g 6-APA and 1.25g D-HPGM and dissolve them in 50mL 0.1M PBS buffer at pH 6.3, adjust the pH to 6.3, and then dilute to 100mL with the above buffer solution. Take 0.1mL KcPA and add it to the above solution. Start the reaction at 25℃ and 200rpm for 30min. Put it in a 90℃ water bath for 2min to inactivate the enzyme and end the reaction. Take 0.5mL of the reaction solution and filter it with a 0.22μm water filter membrane. Use phosphate buffer to dilute to 100mL for HPLC detection to obtain the amoxicillin content. Enzyme activity calculation formula: Penicillin acylase synthase activity per mL Where: V: reaction solution volume, mL; 200: dilution factor; C 样 : Amoxicillin molar concentration, μmol / L; V E : Volume of enzyme added, mL; t: reaction time, min.

[0090] HPLC detection conditions are: Agilent ZORBAX SB-C18 4.6x250 mm chromatographic column, column temperature 25°C. Injection volume 10μL. Mobile phase A (0.02M pH4.7 NaH2PO4-Na2HPO4 buffer), mobile phase B (methanol), initially 90% mobile phase A and 10% mobile phase B for 5 min, 5min to 7min mobile phase B increased from 10% to 50% and then maintained for 10 min, 17min to 19min mobile phase B decreased from 50% to 10%, and finally 90% mobile phase A and 10% mobile phase B were balanced for 5 min, and the total flow rate was 1mL / min.

[0091] Table 2 Comparison of activities between mutants and wild type

[0092]

[0093] Note: The hydrolysis activity of the wild-type KcPA expressed by the recombinant bacteria is 15U / mL (fermentation broth), and the synthesis activity is 80U / mL. For the convenience of comparison, the enzyme activity of the wild-type KcPA is defined as 100 in Table 2, and each mutant is compared with it.

[0094] As can be seen from the above table, for mutants with single mutation sites, the hydrolysis activity and synthesis activity of each mutant are significantly improved compared with the wild type, especially the F146αK mutant on the α subunit and the G385βR mutant on the β subunit. The hydrolysis activity and synthesis activity of the single-point F146αK mutant are 5.8 times and 15.3 times that of the wild type, respectively; the hydrolysis activity and synthesis activity of the G385βR mutant are 4.6 times and about 11.2 times that of the wild type, respectively. Compared with the G385βR mutant, the G385βY mutant has higher hydrolysis activity, but its synthesis activity is not outstanding. When mutations are superimposed at each mutation site, the enzyme activity of the mutant is increased compared with the single-point mutation, especially the five-point mutant F146αK&F24βR&F71βY&N241βK&G385βR, which has higher hydrolysis activity and synthesis activity.

[0095] Example 3

[0096] One-step synthesis of amoxicillin by PGK catalyzed by various mutants and wild-type penicillin acylase

[0097] PGK was added to a pH 7.0 PBS buffer to a concentration of 200 mM, and p-hydroxyphenylglycine methyl ester (D-HPGM) was added to a final concentration of 300 mM. The amount of enzyme added was 30 U / mL (calculated based on the activity of the synthase), and the reaction was stirred at a constant temperature of 28°C for 3 hours. After the reaction was completed, HPLC detection was performed to calculate the yield of amoxicillin.

[0098] HPLC detection conditions are: Agilent ZORBAX SB-C18 4.6x250 mm chromatographic column, column temperature 25°C. Injection volume 10μL. Mobile phase A (0.02M pH4.7 NaH2PO4-Na2HPO4 buffer), mobile phase B (methanol), initially 90% mobile phase A and 10% mobile phase B for 5 minutes, 5min to 7min mobile phase B increased from 10% to 50% and then maintained for 10 minutes, 17 to 19min mobile phase B decreased from 50% to 10%, and finally 90% mobile phase A and 10% mobile phase B were balanced for 5 minutes, and the total flow rate was 1mL / min. The reaction formula is as follows:

[0099]

[0100] The HPLC detection spectrum of mutant KcPA18 is as follows Figure 5 As shown in the figure, DHPG is D-p-hydroxyphenylglycine, AMOX is amoxicillin, DHPGM is D-p-hydroxyphenylglycine methyl ester, PAA is phenylacetic acid, and PGK is penicillin potassium salt. It can be seen from the figure that the content of the intermediate product 6-APA is extremely low, almost non-existent.

[0101] Table 3 The yield of amoxicillin synthesized by each mutant

[0102]

[0103] From the results in the above table, it can be seen that each mutant can catalyze the reaction of penicillin potassium and p-hydroxyphenylglycine methyl ester in a reaction system to synthesize amoxicillin in one step, and the product yield is significantly improved compared with the wild type.

[0104] Example 4

[0105] One-step synthesis of amoxicillin by PGK catalyzed by KcPA18

[0106] The reaction system is different from that in Example 3 only in that the pH of the PBS buffer in this example is 7.5. The HPLC detection conditions are the same as those in Example 3.

[0107] The changes in the content of each substance during the reaction are as follows Figure 6 , reaction yield 98%.

[0108] Example 5

[0109] One-step synthesis of ampicillin by PGK catalyzed by KcPA18

[0110] PGK was added to the PBS buffer at pH 7.5 to make its concentration reach 240 mM. Phenylglycine methyl ester (D-PGM) was added to make its final concentration 480 mM. The amount of enzyme added was 30 U / mL (calculated as synthetase activity). The reaction was stirred at a constant temperature of 25°C for 3 h. Samples were taken and tested regularly during the reaction.

[0111] The HPLC detection conditions are the same as those in Example 3, and the reaction formula is as follows:

[0112]

[0113] The changes in the content of each substance during the reaction are as follows Figure 7 , reaction yield 98%.

[0114] Example 6

[0115] Synthesis of Cefaclor from 7-ACCA Catalyzed by KcPA18

[0116] 7-ACCA was added to the PBS buffer at pH 7.5 to a concentration of 200 mM. D-phenylglycine methyl ester (D-PGM) was added to a final concentration of 240 mM. The amount of enzyme added was 20 U / mL (calculated based on the activity of the synthetase). The reaction was stirred at a constant temperature of 15°C for 2.25 h. Samples were taken and tested regularly during the reaction.

[0117] The HPLC analysis conditions were: 0.01 M sodium phosphate (pH 6.8) and methanol (95:5) as the mobile phase, a flow rate of 1.0 mL / min, an Agilent ZORBAX SB-C18 4.6x250 mm column, and an injection volume of 10 μL. The reaction formula is as follows:

[0118]

[0119] The changes in the content of each substance during the reaction are as follows Figure 8 , reaction yield 95%.

[0120] Example 7

[0121] Effect of KcPA18 on the synthesis of cefradine from 7-ADCA

[0122] 7-ADCA was added to the PBS buffer at pH 8.0 to make its concentration reach 180 mM. D-phenylglycine methyl ester (D-PGM) was added to make its final concentration 270 mM. The amount of enzyme added was 25 U / mL (calculated as synthetase activity). The reaction was stirred at a constant temperature of 10°C for 2.25 h. Samples were taken and tested regularly during the reaction.

[0123] The HPLC analysis conditions were: 0.01 M sodium phosphate (pH 5.5) and methanol (93:7) as the mobile phase, a flow rate of 1.0 mL / min, an Agilent ZORBAX SB-C18 4.6x250 mm column, and an injection volume of 10 μL. The reaction formula is as follows:

[0124]

[0125] The changes in the content of each substance during the reaction are as follows Fig. 9 , reaction yield 99%.

[0126] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A penicillin acylase mutant, characterized in that: Compared with the amino acid sequence shown in SEQ ID NO.1, it contains at least one of the following mutation sites: F146αK, F24βR, F71βY, N241βK, G385βY or G385βR.

2. A nucleotide encoding any one of the penicillin acylase mutants according to claim 1.

3. Use of the penicillin acylase mutant according to claim 1 in the preparation of β-lactam antibiotics.

4. The use according to claim 3, characterized in that: The β-lactam antibiotics include semi-synthetic penicillins and semi-synthetic cephalosporins.

5. The use according to claim 4, characterized in that: The semi-synthetic penicillins include amoxicillin, ampicillin or pivampicillin; the semi-synthetic cephalosporins include cephalexin, cefprozil, cefaclor, cephradine, cefadroxil, cefamandole, cefazolin, cefonic acid, cephalothin or cephalosporin.

6. The use according to claim 4, characterized in that: Only any one of the penicillin acylase mutants is used as the only enzyme in the reaction system to catalyze the reaction between penicillin potassium salt and acyl donor to synthesize semi-synthetic penicillin beta-lactam antibiotics in one step.

7. The use according to claim 6, characterized in that: The acyl donor includes phenylglycine methyl ester or p-hydroxyphenylglycine methyl ester.

8. The use according to claim 4, characterized in that: Any one of the penicillin acylase mutants is used as penicillin acylase to catalyze the reaction of 7-ACCA or 7-ADCA with phenylglycine methyl ester to synthesize semi-synthetic cephalosporin β-lactam antibiotics.

Citation Information

Patent Citations

  • Penicillin G acylase mutant for synthesis and application thereof in preparation of amoxicillin

    CN105274082A

  • Cefradine synthase mutant and coding gene thereof

    CN107099523A

  • Penicillin-g acylases

    CN111051506A

  • Process for the preparation of a betha- lactam antibiotic with mutated penicillin acylase

    US20050124029A1

Cited By

  • Method for synthesizing amoxicillin from penicillin or penicillin salt by enzyme catalysis one-step method

    CN118995868A

  • A method for synthesizing amoxicillin from penicillin or its salt by one-step enzyme catalysis

    CN118995868B

  • Penicillin G acylase AxPGA mutant, expression plasmid, genetically engineered bacterium and application

    CN119932000A

  • Recombinant penicillin G acylase as well as preparation method and application thereof

    CN120137953A

  • A recombinant penicillin G acylase and its preparation method and application

    CN120137953B